Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

Similar articles for PubMed (Select 23144446)

1.

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement.

Schoels MM, van der Heijde D, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Nishimoto N, Smolen JS.

Ann Rheum Dis. 2013 Apr;72(4):583-9. doi: 10.1136/annrheumdis-2012-202470. Epub 2012 Nov 10. Review. Erratum in: Ann Rheum Dis. 2013 Jun;72(6):1110. Murikama, Miho M [corrected to Murakami, Miho].

2.

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.

Smolen JS, Schoels MM, Nishimoto N, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Betteridge N, Bingham CO 3rd, Bykerk V, Choy EH, Combe B, Cutolo M, Graninger W, Lanas A, Martin-Mola E, Montecucco C, Ostergaard M, Pavelka K, Rubbert-Roth A, Sattar N, Scholte-Voshaar M, Tanaka Y, Trauner M, Valentini G, Winthrop KL, de Wit M, van der Heijde D.

Ann Rheum Dis. 2013 Apr;72(4):482-92. doi: 10.1136/annrheumdis-2012-202469. Epub 2012 Nov 21.

3.

Antagonizing IL-6 in ankylosing spondylitis: a short review.

Rajalingham S, Das S.

Inflamm Allergy Drug Targets. 2012 Aug 1;11(4):262-5. Review.

PMID:
22452603
4.

Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis.

Schoels M, Aletaha D, Smolen JS, Wong JB.

Ann Rheum Dis. 2012 Aug;71(8):1303-8. doi: 10.1136/annrheumdis-2011-200490. Epub 2012 Jan 30. Review.

PMID:
22294630
5.

Targeting interleukin-6 in rheumatoid arthritis.

Md Yusof MY, Emery P.

Drugs. 2013 Mar;73(4):341-56. doi: 10.1007/s40265-013-0018-2. Review.

PMID:
23456676
6.

IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions.

Woodrick RS, Ruderman EM.

Bull NYU Hosp Jt Dis. 2012;70(3):195-9. Review.

7.

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, Worthy G, Landewé R, Smolen JS, Emery P, Buch MH.

Ann Rheum Dis. 2010 Jun;69(6):976-86. doi: 10.1136/ard.2009.126573. Epub 2010 May 6. Review. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

PMID:
20447957
8.

New biologics for rheumatoid arthritis.

Choy E.

J R Coll Physicians Edinb. 2011 Sep;41(3):234-7. doi: 10.4997/JRCPE.2011.312.

PMID:
21949922
9.

The role of tocilizumab in the management of rheumatoid arthritis.

Ash Z, Emery P.

Expert Opin Biol Ther. 2012 Sep;12(9):1277-89. doi: 10.1517/14712598.2012.707178. Epub 2012 Jul 31. Review.

PMID:
22849354
10.

Tocilizumab in pediatric rheumatology: the clinical experience.

Gurion R, Singer NG.

Curr Rheumatol Rep. 2013 Jul;15(7):338. doi: 10.1007/s11926-013-0338-y. Review.

PMID:
23715975
11.

Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review.

Gout T, Ostör AJ, Nisar MK.

Clin Rheumatol. 2011 Nov;30(11):1471-4. doi: 10.1007/s10067-011-1827-x. Epub 2011 Aug 11. Review.

PMID:
21833686
12.

Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases.

Alten R, Maleitzke T.

Ann Med. 2013 Jun;45(4):357-63. doi: 10.3109/07853890.2013.771986. Epub 2013 May 8. Review.

PMID:
23650978
13.

Interleukin-6 in rheumatoid arthritis.

Nishimoto N.

Curr Opin Rheumatol. 2006 May;18(3):277-81. Review.

PMID:
16582692
14.

Inhibition of IL6 in rheumatoid arthritis and juvenile idiopathic arthritis.

Mircic M, Kavanaugh A.

Exp Cell Res. 2011 May 15;317(9):1286-92. doi: 10.1016/j.yexcr.2011.02.017. Epub 2011 Mar 22. Review.

PMID:
21439276
15.

Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials.

Steiman AJ, Pope JE, Thiessen-Philbrook H, Li L, Barnabe C, Kalache F, Kung T, Bessette L, Flanagan C, Haraoui B, Hochman J, Leclercq S, Mosher D, Thorne C, Bykerk V.

Rheumatol Int. 2013 May;33(5):1105-20. doi: 10.1007/s00296-012-2619-6. Epub 2013 Jan 6. Review.

PMID:
23292213
16.

Clinical value of blocking IL-6 receptor.

Mima T, Nishimoto N.

Curr Opin Rheumatol. 2009 May;21(3):224-30. doi: 10.1097/BOR.0b013e3283295fec. Review.

PMID:
19365268
17.

Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.

Das S, Vital EM, Horton S, Bryer D, El-Sherbiny Y, Rawstron AC, Ponchel F, Emery P, Buch MH.

Ann Rheum Dis. 2014 May;73(5):909-12. doi: 10.1136/annrheumdis-2013-204417. Epub 2014 Jan 2.

PMID:
24385201
18.

Interleukin 6 inhibition - RA and beyond.

Woodrick RS, Ruderman EM.

Bull NYU Hosp Jt Dis. 2011;69(3):225-9. Review.

19.

[Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].

Lanfant-Weybel K, Lequerré T, Vittecoq O.

Presse Med. 2009 May;38(5):774-87. doi: 10.1016/j.lpm.2009.02.003. Epub 2009 Mar 26. French.

PMID:
19327945
20.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk